Bio-Lase
Latest Information Update: 24 Nov 1995
At a glance
- Originator Yissum Research Development Company
- Developer BioCardia; Savient Pharmaceuticals; Yissum Research Development Company
- Class Antiplatelets
- Mechanism of Action Platelet aggregation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 24 Nov 1995 Discontinued-Preclinical for Thrombosis in Israel (Unknown route)
- 23 May 1995 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
- 23 May 1995 Preclinical development for Thrombosis in Israel (Unknown route)